AbbVie has selected North Carolina as the site for a new $1.4 billion manufacturing campus that will integrate artificial intelligence with advanced production and laboratory technologies to support its immunology, neuroscience, and oncology medicine lines. No timeline for completion was announced. The investment reflects both the scale of AbbVie’s pipeline ambitions and a broader pharmaceutical industry trend toward AI-assisted manufacturing—applying machine learning to process optimization, quality control, and yield prediction in ways that reduce variability and regulatory risk.